Immunome, Inc. IMNM
At closeNov 10, 2026, 6:20 AM EST
Pre-market · Nov 10, 6:20 AM ET
- YTD
- -9.87%
- 1 year
- +17.76%
- Market cap
- 2.28B
- EPS (ttm)
- -2.52
- Shares out
- 118.00M
- Forward P/E
- -7.87
- YTD return
- -9.87%
- 1-year return
- +17.76%
- Volume
- 1.38M
- Avg volume
- 1.37M
- Open
- 18.90
- Previous close
- 18.71
- Day's range
- 18.46 – 19.79
- 52-week range
- 16.11 – 30.06
- Beta
- 2.66
- Analysts
- Strong Buy
- Price target
- 35.33 (+82.5%)
- Earnings date
- Mar 25, 2027
Key statistics
- Enterprise value
- 1.61B
- PEG ratio
- 0.00
- Price / book
- 4.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -143.66M
- Total cash
- 520.00M
- Total debt
- 4.74M
- Return on equity
- -64.03%
- Short % of float
- 17.02%
- 50-day average
- 21.49
- 200-day average
- 22.37
Analyst view
Consensus: strong buy
- Target (low)
- 24.00
- Target (mean)
- 35.33
- Target (high)
- 40.00
- Strong buy3
- Buy13
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 25, 2027
Expected Mar 25, 2027. Consensus EPS estimate -0.5976.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 25, 2027 | Mar 30, 2027 | -0.64438 | — | — | — |
| Nov 10, 2026 | Sep 30, 2026 | -0.60851 | -0.76 | -0.15 | -24.90% |
| Aug 11, 2026 | Jun 30, 2026 | -0.51381 | -0.65 | -0.14 | -26.51% |
| May 12, 2026 | Mar 31, 2026 | -0.60 | -0.48 | +0.12 | +20.00% |
| Mar 3, 2026 | Dec 31, 2025 | -0.59017 | -0.75 | -0.16 | -27.08% |
| Nov 6, 2025 | Sep 30, 2025 | -0.57 | -0.65 | -0.08 | -14.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Wedbush | reit | Outperform | Outperform |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 1, 2026 | Stifel | init | — | Hold |
| Sep 21, 2026 | Alliance Global Partners | init | — | Buy |
| Sep 10, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2026 | Truist Securities | main | Buy | Buy |
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunome.com
News
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know 
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates 
Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid Tumors 
Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target 
Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026
Your note
Sign in to keep a note on IMNM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARCHAS ISAAC | Director | Sale | Aug 11, 2026 | 0 |
| BIENAIME JEAN-JACQUES | Director | Purchase | Jun 4, 2026 | 43,415 |
| HIGGINS JACK | Officer | Conversion of Exercise of derivative security | Sep 10, 2026 | 59,250 |
| HORN KINNEY | Officer | Conversion of Exercise of derivative security | Aug 3, 2026 | 0 |
| LECHLEIDER ROBERT | Officer | Stock Award(Grant) | Jul 22, 2026 | 69,805 |
| ROSETT MAX | Chief Financial Officer | Stock Award(Grant) | Jul 22, 2026 | 101,287 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17.32% | 19,676,883 | 380.94M | Jun 29, 2026 |
| FMR, LLC | 14.96% | 16,987,553 | 328.88M | Jun 29, 2026 |
| Blackrock Inc. | 7.75% | 8,805,492 | 170.47M | Jun 29, 2026 |
| State Street Corporation | 4.84% | 5,494,625 | 106.38M | Jun 29, 2026 |
| Wellington Management Group, LLP | 4.59% | 5,210,216 | 100.87M | Jun 29, 2026 |
| Redmile Group, LLC | 4.32% | 4,911,590 | 95.09M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 6.32% | 7,179,563 | 139.00M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.41% | 5,004,684 | 96.89M | Sep 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 3.44% | 3,907,378 | 75.65M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.26% | 3,703,461 | 71.70M | Jul 30, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 3.25% | 3,692,941 | 71.50M | Sep 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 2.99% | 3,392,151 | 65.67M | Jun 29, 2026 |